Redeye comments on Invisio ahead of its Q1 2023-results (due 4 May) where we expect continued strong...
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and s...
Redeye raises its Base Case, forecasts, and Redeye Rating for ADDvise following a streak of solid re...
EMS industry thriving on strong demand, fading shortages Expect continued growth in Q1e: sales SEK 5...
Q1e 36% org. growth, but limited margin improvement q-o-q We cut '23e-'24e adj.
We cut '23e-'25e EBITA by 15-3% CPI-PPI gap negative for the first time in ~3 years.
Tillväxtresan fortsätter in i 2023 men lönsamheten pressas under Q1.
Redeye comments on Fragbite Groups' updated timeline for its coming web3 games, which now is expecte...
Intäkterna minskade under Q4 men den långsiktigt positiva utsikten är intakt.
Sales +23% y-o-y, +7% vs. ABGSCe Slight gross margin relief Probably relatively small est.
We initiate coverage of Agilyx with a fair value range of NOK 62-84.
Mendus recapped highlights of the positive clinical readouts from its ADVANCE II study in acute myel...
Hansa’s Q1 is soft in terms of product sales. We expect 2023 recurring sales contributions to be squ...
VEF has taken a conservative stance on its NAV while adjusting its holdings growth strategies throug...
Consti reports its Q1 2023 earnings on 27th of April.
Redeye will likely increase its forecasts and Base Case following a solid Q1 report from ADDvise.
Redeye provides an update on Freemelt ahead of its Q1-results (due 10 May), where we lower our sales...
On Tuesday, 18 April, BankNordik upgraded its 2023 net profit guidance to DKK 210-240m (previously D...
Paper prices to decline further, but too late for some customers '23e-'25e revenues down 1-2%, EBIT ...
11% CAGR in net profit for 2022-'25e... ...and 12% dividend yield p.
